Once approved, BRACAnalysis CDx will be used with Pfizer's PARB inhibitor, talazoparib. Talazoparib has a prescription drug user fee act goal date of later this year.
The post Myriad Receives FDA SPMA Approval for BRACAnalysis CDx appeared first on Investing News Network.
Original Article: Myriad Receives FDA SPMA Approval for BRACAnalysis CDx